F-1/A: Evaxion Biotech A/S Announces Proposed Offering of ADSs and Warrants

Evaxion Biotech A/S plans to offer American Depositary Shares (ADSs) and warrants in a best efforts offering.

Summary

• Evaxion Biotech A/S is planning a best efforts offering of up to 1,799,336 American Depositary Shares (ADSs) representing 89,966,800 ordinary shares, along with warrants to purchase up to 899,668 ADSs representing 44,983,400 ordinary shares.
• Each two ADSs will be sold with one warrant to purchase one ADS, and the ADSs and warrants are immediately separable but must be purchased together.
• The warrants will have an exercise price to be determined and will be immediately exercisable for five years.
• The assumed public offering price is $6.03 per ADS and accompanying warrant, based on the January 24, 2025 closing price.
• The company is also offering pre-funded warrants to certain purchasers who would otherwise exceed ownership limits, with the price of each pre-funded warrant equal to the ADS price minus $1.72, and an exercise price of $1.72 per ADS.
• The offering is expected to terminate on February 14, 2025, and Lake Street Capital Markets, LLC and JonesTrading Institutional Services LLC are acting as placement agents.
• The placement agents will receive a cash fee of 7.0% of the gross proceeds and reimbursement for legal fees and expenses up to $100,000.
• The company estimates total offering expenses, excluding placement agent fees, to be approximately $0.7 million.
• There is no minimum offering amount required to close the offering, and the company may sell fewer than all of the securities offered.
• Evaxion Biotech A/S had cash and cash equivalents of $11.9 million as of January 27, 2025.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing for a proposed offering. The sentiment is neutral as it primarily presents factual information.

Positives

• The company has engaged placement agents to assist with the offering.
• The company has the flexibility to terminate the offering early.
• The company has the ability to use the proceeds from the sale of securities immediately.

Negatives

• There is no minimum offering amount required, which may significantly reduce the proceeds received by the company.
• Investors will not receive a refund if the company does not sell enough securities to pursue its business goals.
• The investors could be in a position where they have invested in the company, but the company is unable to fulfill all of its contemplated objectives due to a lack of interest in this offering.
• There is no established public trading market for the warrants or pre-funded warrants, and the company does not expect a market to develop.
• Without an active trading market, the liquidity of the warrants will be limited.

Risks

• The company may sell fewer than all of the securities offered, which may significantly reduce the amount of proceeds received.
• Investors may not receive a refund if the company does not sell an amount of securities sufficient to pursue its business goals.
• The investors could be in a position where they have invested in the company, but the company is unable to fulfill all of its contemplated objectives due to a lack of interest in this offering.
• There is uncertainty about whether the company would be able to use such funds to effectively implement its business plan.
• There is no established public trading market for the warrants or pre-funded warrants, and the company does not expect a market to develop.
• Continued non-compliance with Nasdaq listing requirements could result in delisting from Nasdaq Capital Markets.

Future Outlook

The company intends to use the net proceeds of this offering to advance its preclinical and clinical pipeline, and for continuing operating expenses and working capital.

Industry Context

This announcement is typical for biotech companies seeking funding to advance their research and development programs. The use of ADSs and warrants is a common structure to attract investors.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's ability to fund its operations and advance its pipeline will be impacted by the success of the offering.

Next Steps

• The company will proceed with the offering, seeking to sell the ADSs and warrants.
• The company will use the proceeds to advance its pipeline and for working capital.

Key Dates

Keywords

ADSs, warrants, offering, Evaxion Biotech, pre-funded warrants, placement agents, securities, ordinary shares